This year was a complicated one for providers, from tariff threats and research funding changes to the rise of AI.

Experts spoke with Healthcare Brew about the biggest standout moments and trends for providers in 2025.

Ophir Klein, executive director of Cedars-Sinai Guerin Children’s and executive vice dean of Children’s Services, Cedars-Sinai

This year has brought continued evolution in child healthcare, from how hospitals deliver care to how they use technology and work with payers and staff. Researchers and clinicians are striving to work closely together to move discoveries from the lab to the bedside. This collaboration speeds up the adoption of new approaches in inherited and acquired conditions, helping clinicians provide faster, more effective care for complex conditions.

Use of artificial intelligence is becoming a regular part of practice, and it will inevitably evolve into a fundamental component for all areas of healthcare—from clinical decision-making and diagnostics to hospital administration, education, and patient engagement.

See what leaders had to say.—CM

Another year, another batch of new treatments coming to market.

The year 2025 may have been a bit of a roller coaster, but along the way, we still picked up a few new drugs and medical devices with major potential.

But what were some of the most impactful treatments of the year? Read on to find out.

Custom gene editing. This year brought the world’s first-ever recorded customized gene edit tailored to a single patient, courtesy of a team at the Children’s Hospital of Philadelphia and Penn Medicine.

The infant patient, KJ, received CRISPR gene editing for a rare, disabling, and often deadly genetic disorder known as CPS1 deficiency. His doctors detailed the treatment in a May New England Journal of Medicine article.

KJ got his first dose of the multidose treatment in February. It’s too soon to say how many doses will be needed, per the New York Times.

Here’s the full list.—CC

Each week, we schedule our rounds with Healthcare Brew readers. Want to be featured in an upcoming edition? Click here to introduce yourself.

Eye doctors are the first line of defense for the 2+ billion people worldwide with vision impairment.

The reasons for vision trouble are as varied as each person’s lens prescription: age-related decline, cataracts, and even diabetes can lead to issues. Every year brings new data, drugs, surgical techniques, and technology to help create personalized solutions for each patient.

To find out more about the field, we sat down with Elizabeth Yeu, an ophthalmologist who has been chief medical officer of biopharma Tarsus Pharmaceuticals since November 2024.

Most of the company’s revenue comes from a prescription eye drop treatment, Xdemvy, approved by the FDA in 2023 to treat a common inflammatory eyelid condition called demodex blepharitis. Tarsus is also working on developing drugs for ocular rosacea, Lyme disease, and malaria.

Yeu shared her thoughts on her role at Tarsus as well as the role AI and big data can play in the future of eye care.

See the full conversation here.—CC